Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis
- 15 May 2009
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 10 (8), 1377-1385
- https://doi.org/10.1517/14656560902980228
Abstract
Bazedoxifene acetate (WAY-140424; TSE-424) is an oral, nonsteroidal, indole-based selective estrogen receptor modulator (SERM) being developed for the prevention and treatment of osteoporosis. Preclinical studies on bazedoxifene have demonstrated estrogen agonist effects on the skeleton and lipid metabolism but not on breast and uterine endometrium. In combination with estrogen, bazedoxifene antagonizes the stimulatory action of estrogens on proliferation of breast cancer cells and endometrium. Phase III clinical studies have shown favorable effects on the skeleton without stimulation of endometrium and breast. Bazedoxifene prevents bone loss in postmenopausal women without osteoporosis and reduces vertebral fractures in women with postmenopausal osteoporosis. In women at high risk of fracture with multiple risk factors, bazedoxifene reduces nonvertebral fracture risk in post-hoc analysis. Bazedoxifene in combination with conjugated estrogens represents a new form of therapeutic agents for the treatment of postmenopausal symptoms and prevention of postmenopausal osteoporosis. Clinical trials with bazedoxifene/conjugated estrogens have shown beneficial effects on bone mineral density and bone turnover markers with improvement in vasomotor symptoms and little or no stimulation of breast and endometrium. © 2009 Informa UK Ltd. All rights reserved.link_to_subscribed_fulltexKeywords
This publication has 15 references indexed in Scilit:
- Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary glandMolecular and Cellular Endocrinology, 2008
- Transient Disturbance in Physeal Morphology Is Associated With Long-Term Effects of Nitrogen-Containing Bisphosphonates in Growing RabbitsJournal of Bone and Mineral Research, 2005
- Bazedoxifene Acetate: A Selective Estrogen Receptor Modulator with Improved SelectivityEndocrinology, 2005
- Justification for the use of HRT in the long-term prevention of osteoporosisMaturitas, 2005
- Selective estrogen receptor modulators protect hippocampal neurons from kainic acid excitotoxicity: Differences with the effect of estradiolJournal of Neurobiology, 2004
- Lack of Pharmacokinetic Interaction Co-Administered of Sirolimus and TacrolimusClinical Pharmacology & Therapeutics, 2003
- Developing a SERM: Stringent Preclinical Selection Criteria Leading to an Acceptable Candidate (WAY‐140424) for Clinical EvaluationAnnals of the New York Academy of Sciences, 2001
- Design, Synthesis, and Preclinical Characterization of Novel, Highly Selective Indole EstrogensJournal of Medicinal Chemistry, 2001
- Adverse events reported by postmenopausal women in controlled trials with raloxifeneObstetrics & Gynecology, 1999
- α-Adrenergic mediation of the tail skin temperature response to naloxone in morphine-dependent ratsBrain Research, 1987